• Events
• News

Genzyme and Bayer HealthCare Enter New Strategic Agreement
March 31, 2009
Genzyme Assumes Primary Responsibility for the Development and Commercialization of Alemtuzumab for Multiple Sclerosis
Acquires Bayer’s Hematologic Oncology Portfolio
First of Two Alemtuzumab MS Phase 3 Trials Completes Enrollment

FDA Approves Genzyme’s Mozobil
December 15, 2008
Product Provides Enhanced Mobilization of Stem Cells for Autologous Transplantation in Non-Hodgkin’s Lymphoma and Multiple Myeloma Patients

Genzyme Reports Clolar^® Data Further Supporting Potential of Product to Treat Adult AML Patients
December 8, 2008
Updated Phase 3 Mozobil™ Data and Post-Hoc Analysis Presented
American Society of Hematology Meeting Highlights Genzyme’s Hematology/Oncology Presence

Genzyme Seeks U.S. Approval for Clolar^® to Treat Adult AML
November 24, 2008
Indication Would Address Significant Unmet Medical Need and Expand Product Use

Genzyme and Osiris Partner to Develop and Commercialize First-in-Class Adult Stem Cell Products
November 4, 2008

Study Results: Multiple Sclerosis Patients Have Significant and Sustained Reduction in Disability and Risk Of Relapse On Alemtuzumab Versus Approved Therapy, Rebif^®
October 22, 2008
Final Phase 2 Data Published in New England Journal of Medicine
International Phase 3 Alemtuzumab Studies Enrolling

Mozobil Receives Priority Review with FDA Action Expected by Year End; Synvisc-ONE FDA Action also Expected by Year End
September 23, 2008
Mozobil Receives Priority Review with FDA Action Expected by Year End; Synvisc-ONE FDA Action also Expected by Year End

Genzyme Files Applications for Approval of Mozobil in the United States and Europe
June 17, 2008

Genzyme Withdraws Bioenvision’s European Filing of Evoltra® in Elderly AML Patients
March 19, 2008
Will Resubmit With New Data from Ongoing Studies